Cognitive deficits in Parkinson’s disease: current perspectives

References

• Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–1264.
   PubMed Web of Science ®Google Scholar
• Perez F, Helmer C, Foubert-Samier A, Auriacombe S, Dartigues JF, Tison F. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimers Dement. 2012;8(6):463–469.
   PubMed Web of Science ®Google Scholar
• Auyeung M, Tsoi TH, Mok V, et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry. 2012;83(6):607–611.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255–1263.
   PubMed Web of Science ®Google Scholar
• Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111–128.
   PubMedGoogle Scholar
• Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615–1622.
   PubMed Web of Science ®Google Scholar
• Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol. 2012;25(4):208–214.
   PubMed Web of Science ®Google Scholar
• Szeto JY, Mowszowski L, Gilat M, Walton CC, Naismith SL, Lewis SJ. Mild cognitive impairment in Parkinson’s disease: impact on caregiver outcomes. J Parkinsons Dis. 2016;6(3):589–596.
   PubMedGoogle Scholar
• Litvan I, Goldman J, Tröster A, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force Guidelines. Mov Disord. 2012;27(3):349–356.
   PubMed Web of Science ®Google Scholar
• Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology. 2013;81(4):346–352.
   PubMed Web of Science ®Google Scholar
• Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014;82(4):308–316.
   PubMed Web of Science ®Google Scholar
• Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–852.
   PubMed Web of Science ®Google Scholar
• Erro R, Santangelo G, Barone P, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease? J Geriatr Psychiatry Neurol. 2014;27(4):276–281.
   PubMed Web of Science ®Google Scholar
• Hong JY, Sunwoo MK, Chung SJ, et al. Subjective cognitive decline predicts future deterioration in cognitively normal patients with Parkinson’s disease. Neurobiol Aging. 2014;35(7):1739–1743.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–1707. quiz 1837.
   PubMed Web of Science ®Google Scholar
• Geurtsen GJ, Hoogland J, Goldman JG, et al. Parkinson’s disease mild cognitive impairment: application and validation of the criteria. J Parkinson Dis. 2014;4(2):131–137.
   Web of Science ®Google Scholar
• Szeto JYY, Mowszowski L, Gilat M, Walton CC, Naismith SL, Lewis SJG. Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(1):31–35.
   PubMed Web of Science ®Google Scholar
• Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord. 2013;28(5):626–633.
   PubMed Web of Science ®Google Scholar
• Janvin C, Larsen J, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord. 2006;21(9):1343–1349.
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol. 2013;70(5):580–586.
   PubMed Web of Science ®Google Scholar
• Elgh E, Domellof M, Linder J, Edstrom M, Stenlund H, Forsgren L. Cognitive function in early Parkinson’s disease: a population-based study. Eur J Neurol. 2009;16(12):1278–1284.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007;130(pt 7):1787–1798.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(pt 11):2958–2969.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–1069.
   PubMed Web of Science ®Google Scholar
• Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9(12):1200–1213.
   PubMed Web of Science ®Google Scholar
• Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11(2):79–92.
   PubMed Web of Science ®Google Scholar
• Nombela C, Rowe JB, Winder-Rhodes SE, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain. 2014;137(pt 10):2743–2758.
   PubMedGoogle Scholar
• Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Kvaløy J, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol. 2007;254(1):38–45.
   PubMed Web of Science ®Google Scholar
• Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry. 2011;82(9):1033–1037.
   PubMed Web of Science ®Google Scholar
• Kempster P, O’Sullivan S, Holton J, Revesz T, Lees A. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133(6):1755–1762.
   PubMed Web of Science ®Google Scholar
• Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(5):585–589.
   PubMed Web of Science ®Google Scholar
• Alves G, Larsen J, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21(8):1123–1130.
   PubMed Web of Science ®Google Scholar
• Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord. 2011;26(14):2496–2503.
   PubMed Web of Science ®Google Scholar
• Taylor JP, Rowan EN, Lett D, O’Brien JT, McKeith IG, Burn DJ. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype. J Neurol Neurosurg Psychiatry. 2008;79(12):1318–1323.
   PubMed Web of Science ®Google Scholar
• Irwin D, Lee V, Trojanowski J. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013;14(9):626–636.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, de Vos R, Jansen Steur E, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
   PubMed Web of Science ®Google Scholar
• Braak H, Rüb U, Jansen Steur E, Del Tredici K, de Vos R. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005;64(8):1404–1410.
   PubMed Web of Science ®Google Scholar
• Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115(4):399–407.
   PubMed Web of Science ®Google Scholar
• Compta Y, Parkkinen L, O’Sullivan S, et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain. 2011;134(5):1493–1505.
   PubMedGoogle Scholar
• Clinton L, Blurton-Jones M, Myczek K, Trojanowski J, LaFerla F. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281–7289.
   PubMed Web of Science ®Google Scholar
• Matthews F, Brayne C, Lowe J, McKeith I, Wharton S, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med. 2009;6(11):e1000180.
   PubMed Web of Science ®Google Scholar
• Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson’s disease. Brain. 1992;115(pt 6):1727–1751.
   PubMedGoogle Scholar
• Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson’s disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology. 1992;107(2–3):394–404.
   PubMed Web of Science ®Google Scholar
• Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia. 2003;41(11):1431–1441.
   PubMed Web of Science ®Google Scholar
• Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson’s disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia. 2000;38(5):596–612.
   PubMed Web of Science ®Google Scholar
• Kwak Y, Muller ML, Bohnen NI, Dayalu P, Seidler RD. Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson’s disease. J Neurophysiol. 2010;103(2):942–949.
   PubMed Web of Science ®Google Scholar
• Fearnley J, Lees A. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(5):2283–2301.
   PubMedGoogle Scholar
• Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson’s disease: a multi-tracer positron emission tomography study. Brain. 2009;132(11):2970–2979.
   PubMedGoogle Scholar
• Vaillancourt DE, Schonfeld D, Kwak Y, Bohnen NI, Seidler R. Dopamine overdose hypothesis: evidence and clinical implications. Mov Disord. 2013;28(14):1920–1929.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Barker RA. Understanding the dopaminergic deficits in Parkinson’s disease: insights into disease heterogeneity. J Clin Neurosci. 2009;16(5):620–625.
   PubMed Web of Science ®Google Scholar
• Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75(5):807–821.
   PubMed Web of Science ®Google Scholar
• Ko WK, Camus SM, Li Q, et al. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models. Neuropharmacology. 2016;110(pt A):48–58.
   PubMedGoogle Scholar
• Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord. 2014;29(5):634–650.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–455.
   PubMed Web of Science ®Google Scholar
• Kehagia AA, Housden CR, Regenthal R, et al. Targeting impulsivity in Parkinson’s disease using atomoxetine. Brain. 2014;137(7):1986–1997.
   PubMedGoogle Scholar
• Rae CL, Nombela C, Rodriguez PV, et al. Atomoxetine restores the response inhibition network in Parkinson’s disease. Brain. 2016;139(pt 8):2235–2248.
   PubMedGoogle Scholar
• Ye Z, Altena E, Nombela C, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease. Brain. 2014;137(pt 4):1145–1155.
   PubMedGoogle Scholar
• Ye Z, Rae CL, Nombela C, et al. Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease with clinical and neuroimaging measures. Hum Brain Mapp. 2016;37(3):1026–1037.
   PubMed Web of Science ®Google Scholar
• Varrone A, Svenningsson P, Marklund P, et al. 5-HT1B receptor imaging and cognition: a positron emission tomography study in control subjects and Parkinson’s disease patients. Synapse. 2015;69(7):365–374.
   PubMed Web of Science ®Google Scholar
• Muller ML, Bohnen NI. Cholinergic dysfunction in Parkinson’s disease. Curr Neurol Neurosci Rep. 2013;13(9):377.
   PubMed Web of Science ®Google Scholar
• Totah NK, Kim YB, Homayoun H, Moghaddam B. Anterior cingulate neurons represent errors and preparatory attention within the same behavioral sequence. J Neurosci. 2009;29(20):6418–6426.
   PubMed Web of Science ®Google Scholar
• Bloem B, Poorthuis RB, Mansvelder HD. Cholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activity. Front Neural Circuits. 2014;8:17.
   PubMed Web of Science ®Google Scholar
• Howe WM, Berry AS, Francois J, et al. Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. J Neurosci. 2013;33(20):8742–8752.
   PubMed Web of Science ®Google Scholar
• Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol. 1984;15(5):415–418.
   PubMed Web of Science ®Google Scholar
• Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson’s disease. Ann Neurol. 1989;26(1):41–46.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745–1748.
   PubMed Web of Science ®Google Scholar
• Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81(2):160–165.
   PubMed Web of Science ®Google Scholar
• Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135–143.
   PubMed Web of Science ®Google Scholar
• Chung SJ, Armasu SM, Biernacka JM, et al. Genomic determinants of motor and cognitive outcomes in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(7):881–886.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Tang BS, Yang Y, et al. Relationship between Alzheimer’s disease GWAS-linked top hits and risk of Parkinson’s disease with or without cognitive decline: a Chinese population-based study. Neurobiol Aging. 2016;39: 217.e9–11.
   Google Scholar
• Chung SJ, Kim MJ, Kim J, et al. Association of type 2 diabetes GWAS loci and the risk of Parkinson’s and Alzheimer’s diseases. Parkinsonism Relat Disord. 2015;21(12):1435–1440.
   PubMed Web of Science ®Google Scholar
• Kasten M, Kertelge L, Bruggemann N, et al. Nonmotor symptoms in genetic Parkinson disease. Arch Neurol. 2010;67(6):670–676.
   PubMedGoogle Scholar
• Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7(7):583–590.
   PubMed Web of Science ®Google Scholar
• Shanker V, Groves M, Heiman G, et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson’s disease. Mov Disord. 2011;26(10):1875–1880.
   PubMed Web of Science ®Google Scholar
• Srivatsal S, Cholerton B, Leverenz JB, et al. Cognitive profile of LRRK2-related Parkinson’s disease. Mov Disord. 2015;30(5):728–733.
   PubMed Web of Science ®Google Scholar
• Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol. 2004;55(2):174–179.
   PubMed Web of Science ®Google Scholar
• Waxman EA, Giasson BI. Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta. 2009;1792(7):616–624.
   PubMed Web of Science ®Google Scholar
• Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the Parkin gene. N Engl J Med. 2000;342(21):1560–1567.
   PubMed Web of Science ®Google Scholar
• Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile Parkinsonism linked to chromosome 6q. Neurology. 1998;51(3):890–892.
   PubMed Web of Science ®Google Scholar
• Grunewald A, Kasten M, Ziegler A, Klein C. Next-generation phenotyping using the parkin example: time to catch up with genetics. JAMA Neurol. 2013;70(9):1186–1191.
   PubMed Web of Science ®Google Scholar
• Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361(17):1651–1661.
   PubMed Web of Science ®Google Scholar
• Seto-Salvia N, Pagonabarraga J, Houlden H, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson’s disease course. Mov Disord. 2012;27(3):393–399.
   PubMed Web of Science ®Google Scholar
• Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort. Brain. 2013;136(pt 2):392–399.
   PubMed Web of Science ®Google Scholar
• Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 2010;120(5):641–649.
   PubMed Web of Science ®Google Scholar
• Migdalska-Richards A, Schapira AH. The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem. 2016;139(suppl 1):77–90.
   PubMedGoogle Scholar
• Loy CT, Schofield PR, Turner AM, Kwok JBJ. Genetics of dementia. Lancet. 2014;383(9919):828–840.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol. 2006;63(2):189–193.
   PubMed Web of Science ®Google Scholar
• Kurz MW, Dekomien G, Nilsen OB, Larsen JP, Aarsland D, Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J Geriatr Psychiatry Neurol. 2009;22(3):166–170.
   PubMed Web of Science ®Google Scholar
• Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson’s disease. Mov Disord. 2012;27(4):512–518.
   PubMed Web of Science ®Google Scholar
• Collins LM, Williams-Gray CH. The genetic basis of cognitive impairment and dementia in Parkinson’s disease. Front Psychiatry. 2016; 7:89.
   PubMed Web of Science ®Google Scholar
• Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol. 2014;71(11):1405–1412.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217–231.
   PubMed Web of Science ®Google Scholar
• Lin CH, Wu RM. Biomarkers of cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(5):431–443.
   PubMed Web of Science ®Google Scholar
• Mak E, Su L, Williams GB, et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain. 2015;138(pt 10):2974–2986.
   PubMedGoogle Scholar
• Pereira JB, Aarsland D, Ginestet CE, et al. Aberrant cerebral network topology and mild cognitive impairment in early Parkinson’s disease. Hum Brain Mapp. 2015;36(8):2980–2995.
   PubMed Web of Science ®Google Scholar
• Hanganu A, Bedetti C, Degroot C, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally. Brain. 2014;137(pt 4):1120–1129.
   PubMedGoogle Scholar
• Zarei M, Ibarretxe-Bilbao N, Compta Y, et al. Cortical thinning is associated with disease stages and dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84(8):875–881.
   PubMed Web of Science ®Google Scholar
• Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A. Grey matter changes in cognitively impaired Parkinson’s disease patients. PLoS One. 2014;9(1):e85595.
   PubMed Web of Science ®Google Scholar
• Agosta F, Canu E, Stefanova E, et al. Mild cognitive impairment in Parkinson’s disease is associated with a distributed pattern of brain white matter damage. Hum Brain Mapp. 2014;35(5):1921–1929.
   PubMed Web of Science ®Google Scholar
• Chen B, Fan GG, Liu H, Wang S. Changes in anatomical and functional connectivity of Parkinson’s disease patients according to cognitive status. Eur J Radiol. 2015;84(7):1318–1324.
   PubMed Web of Science ®Google Scholar
• Olde Dubbelink KT, Schoonheim MM, Deijen JB, Twisk JW, Barkhof F, Berendse HW. Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology. 2014;83(22):2046–2053.
   PubMed Web of Science ®Google Scholar
• Rektorova I, Krajcovicova L, Marecek R, Mikl M. Default mode network and extrastriate visual resting state network in patients with Parkinson’s disease dementia. Neurodegener Dis. 2012;10(1–4):232–237.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Müller MLTM, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson’s disease without dementia. J Cereb Blood Flow Metab. 2012;32(8):1609–1617.
   PubMed Web of Science ®Google Scholar
• Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79(12):1331–1338.
   PubMed Web of Science ®Google Scholar
• Gomperts S, Locascio J, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80(1):85–91.
   PubMed Web of Science ®Google Scholar
• Shah N, Frey KA, Muller ML, et al. Striatal and cortical beta-amyloidopathy and cognition in Parkinson’s disease. Mov Disord. 2016;31(1):111–117.
   PubMed Web of Science ®Google Scholar
• Gomperts SN, Locascio JJ, Makaretz SJ, et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol. 2016;73(11):1334–1341.
   PubMed Web of Science ®Google Scholar
• Marquie M, Locascio JJ, Rentz DM, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther. 2014;6(5–8):52.
   PubMed Web of Science ®Google Scholar
• Song IU, Kim YD, Cho HJ, Chung SW, Chung YA. An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord. 2013;27(1):51–55.
   PubMed Web of Science ®Google Scholar
• Backstrom DC, Eriksson Domellof M, Linder J, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 2015;72(10):1175–1182.
   PubMed Web of Science ®Google Scholar
• Stewart T, Liu C, Ginghina C, et al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol. 2014;184(4):966–975.
   PubMed Web of Science ®Google Scholar
• Skogseth RE, Bronnick K, Pereira JB, et al. Associations between cerebrospinal fluid biomarkers and cognition in early untreated Parkinson’s disease. J Parkinsons Dis. 2015;5(4):783–792.
   PubMedGoogle Scholar
• Murray DK, Sacheli MA, Eng JJ, Stoessl AJ. The effects of exercise on cognition in Parkinson’s disease: a systematic review. Transl Neurodegener. 2014;3:5–5.
   PubMedGoogle Scholar
• Cruise KE, Bucks RS, Loftus AM, Newton RU, Pegoraro R, Thomas MG. Exercise and Parkinson’s: benefits for cognition and quality of life. Acta Neurol Scand. 2011;123(1):13–19.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Quadros AC Jr, Santos RF, Stella F, Gobbi LT, Gobbi S. Benefits of physical exercise on executive functions in older people with Parkinson’s disease. Brain Cogn. 2009;69(2):435–441.
   PubMed Web of Science ®Google Scholar
• Reynolds GO, Otto MW, Ellis TD, Cronin-Golomb A. The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson’s disease. Mov Disord. 2016;31(1):23–38.
   PubMed Web of Science ®Google Scholar
• Lampit A, Hallock H, Valenzuela M. Computerized cognitive training in cognitively healthy older adults: a systematic review and meta-analysis of effect modifiers. PLoS Med. 2014;11(11):e1001756.
   PubMed Web of Science ®Google Scholar
• Coyle H, Traynor V, Solowij N. Computerized and virtual reality cognitive training for individuals at high risk of cognitive decline: systematic review of the literature. Am J Geriatr Psychiatry. 2015;23(4):335–359.
   PubMed Web of Science ®Google Scholar
• Leung IHK, Walton CC, Hallock H, Lewis SJG, Valenzuela M, Lampit A. Cognitive training in Parkinson disease: a systematic review and meta-analysis. Neurology. 2015;85(21):1843–1851.
   PubMed Web of Science ®Google Scholar
• Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230–1238.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004; 351(24):2509–2518.
   PubMed Web of Science ®Google Scholar
• Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30(7):912–918.
   PubMed Web of Science ®Google Scholar
• Burn DJ. The treatment of mild cognitive impairment associated with Parkinson’s disease. Mov Disord. 2015;30(7):881–882.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A. Rasagiline for mild cognitive impairment in Parkinson’s disease: a placebo-controlled trial. Mov Disord. 2016;31(5):709–714.
   PubMed Web of Science ®Google Scholar
• Goldman JG, Weintraub D. Advances in the treatment of cognitive impairment in Parkinson’s disease. Mov Disord. 2015;30(11):1471–1489.
   PubMed Web of Science ®Google Scholar
• Lindstrom V, Ihse E, Fagerqvist T, et al. Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson’s disease and other Lewy body disorders. Immunotherapy. 2014;6(2):141–153.
   PubMed Web of Science ®Google Scholar
• Valera E, Spencer B, Masliah E. Immunotherapeutic approaches targeting amyloid-beta, alpha-synuclein, and Tau for the treatment of neurodegenerative disorders. Neurotherapeutics. 2016;13(1):179–189.
   PubMed Web of Science ®Google Scholar